Filter
836
Text search:
pharmaceutical
regulations
Featured
71
224
Language
Document type
373
184
146
50
50
12
10
6
3
1
1
Countries
47
32
26
26
24
23
23
19
19
18
18
17
15
14
14
14
13
12
11
11
11
9
9
8
8
8
7
6
6
6
5
5
5
5
4
4
4
4
4
3
3
3
3
3
3
2
2
2
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Authors & Publishers
Publication Years
Category
384
43
33
26
24
15
6
Toolboxes
133
91
72
34
26
21
19
18
18
16
15
12
12
12
11
9
8
6
5
2
2
2
2
1
This document builds on the Background document prepared for the September 4-5, 2014 Consultation. It includes proposed elements to consider during the development of a framework to assist decision-making at global and national level.
The aim of the document is to assist Member States and releva
...
Infectious Diseases of Poverty 2014, 3:42
http://www.idpjournal.com/content/3/1/42
Strengthening health-system emergency preparedness.
This document proposes surveillance objectives and describes global standards for a minimal basic respiratory disease surveillance system for the monitoring of influenza. The agreement on objectives allows for the prioritization of the many facets of influenza that might be measured and tracked. Use
...
Technology landscape
How to address the global crisis in antibiotic research and development.
The report includes a comprehensive summary and critical evaluation of recent initiatives to overcome the barriers to achieve sustainable access to antibiotics. As antibiotic resistance will continue to develop as long as we
...
A key purpose of the Recovery Toolkit is to support countries in the reactivation of health services which may have suffered as a result of the emergency. These services include ongoing programmes such as immunization and vaccinations, maternal and child health services, and noncommunicable diseases
...
WHO Secretariat Information paper July 2016
Economic Issues, Policies and Option for Action
Global Action Plan on Antimicrobial Resistance
recommended
The goal of the draft global action plan is to ensure, for as long as possible, continuity of successful treatment and prevention of infectious diseases with effective and safe medicines that are quality-assured, used in a responsible way, and accessible to all who need them.
